Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan

Chinese Journal of Contemporary Pediatrics

Volumn 12, Issue 6, 2010, Pages 429-432

  Wang, Yan ^a   Gao, Li ^a   Liu, Yan Ping ^a   Huang, Nan Nan ^a   Xu, Shu Jing ^a   Ma, Dong Ju ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Child; Epilepsy; Genetic polymorphism; UGTIA6; Valproic acid

Indexed keywords

VALPROIC ACID; ANTICONVULSIVE AGENT; GLUCURONOSYLTRANSFERASE; UGT1A6 PROTEIN, HUMAN;

ARTICLE; CHILD; CHINESE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; EPILEPSY; GENE; GENE SEQUENCE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; UGTIA6 GENE; ADOLESCENT; CHINA; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CHINA; EPILEPSY; GLUCURONOSYLTRANSFERASE; HUMANS; POLYMORPHISM, GENETIC; VALPROIC ACID;

EID: 77956625260     PISSN: 10088830     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R (2004). Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners. http://www.nice.org.uk/.
2. Sánchez-Alcaraz A, Quintana MB, López E, Rodríguez I. Valproic acid clearance in children with epilepsy[J]. Clin Pharm Ther, 1998, 23(1): 31-34. (Pubitemid 28380372)
3. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V co allele) on dose-adjusted cyclosporin Atrough ncentrations or rejection incidence in stable renal transplant recipients[J]. Clin Chem, 2001, 47(6): 1048-1052.
4. Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identication of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells[J]. Pharmacogenetics, 2004, 14(8): 487-499. (Pubitemid 39100001)
5. Ethell BT, Anderson GD, Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases[J]. Biochem Pharmacol, 2003, 65(9): 1441-1449. (Pubitemid 36555832)
6. Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, et al. Penipenem-betamipron and decreases in serum valproic acid concentration[J]. Ther Drug Monit, 1998, 20(4): 396400.
7. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferase: metabolism, expression, and disease[J]. Annu Rev Pharmacol Toxicol, 2000, 40: 581-616.
8. Urawa N, Kobayashi Y, Araki J, Sugimoto R, Iwasa M, Kaito M, et al. Linkage disequilibrium of UGT1A1 * 6 and UGT1A1 * 28 in relation to UGT1A6 and UGT1A7 polymorphisms[J]. Oncol Rep, 2006, 16(4): 801-806.
9. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyl -transferase: pharmacological implications[J]. Pharmacogenetics, 1997, 7(6): 485-495.
10. Nagar S, Zalatoris J, Blanchard R. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells[J]. Pharmacogenetics, 2004, 14(8): 487-499. (Pubitemid 39100001)
11. Krishnaswamy S, Hao Q, AI-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, et al. UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most coluluon nonsynonymous UGTIA6 polymorphisms (S7A, T181A, and R184S)[J]. Pharmacol Exp Ther, 2005, 313(3): 1340-1346.
12. Peters WH, Morsche RH, Roelofs HM. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome[J]. J Hepatol, 2003, 38(1): 3-8.
13. Krishnaswamy S, Hao Q, Von Moltke LL, Greenblatt DJ, Court MH. Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6 [J]. Drug Metab Dispos 2004, 32(8): 862-869. (Pubitemid 38955616)
14. Chung JY, Cho JY, Yu KS, Kim JR, Um KS, Sohn DR, et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects[J]. Clin Pharmacol Ther, 2008, 83(4): 595-600.
15. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications[J]. Clin Pharmacokinet, 2007, 46(4): 271-279. (Pubitemid 46507006)
16. Aksenova MG, Burd SG, Kachalin Elu, Avakian GN, Badalian OL, Savenkov AA, et al. An association between the FABP2 gene polymorphism and efficacy of valproates[J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2007, 107(1): 42-45.